Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis

Non‐alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end‐stage liver disease (ESLD). A large proportion of early‐stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom in 2018.

[1]  B. Jönsson,et al.  Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study , 2020, JHEP reports : innovation in hepatology.

[2]  V. Wong,et al.  NAFLD — sounding the alarm on a silent epidemic , 2020, Nature Reviews Gastroenterology & Hepatology.

[3]  F. Tacke,et al.  A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. , 2020, Journal of hepatology.

[4]  Z. Younossi,et al.  Hypothetical treatment of patients with non‐alcoholic steatohepatitis: Potential impact on important clinical outcomes , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[5]  Z. Younossi,et al.  The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.

[6]  N. Krieger,et al.  The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study , 2019, JHEP reports.

[7]  Z. Younossi,et al.  Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States , 2019, Hepatology.

[8]  Martin Hurst,et al.  The Green Book: Central Government Guidance on Appraisal and Evaluation , 2019 .

[9]  M. Buti,et al.  Healthcare value of implementing hepatitis C screening in the adult general population in Spain , 2018, PLoS ONE.

[10]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[11]  M. Schlander,et al.  New Estimates of the Willingness-to-Pay for a Statistical Life Year: A Systematic Review of the Empirical Economic Literature , 2018 .

[12]  Rohit Loomba,et al.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease , 2017, Hepatology.

[13]  A. Diehl,et al.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis , 2017, The New England journal of medicine.

[14]  A. Bottle,et al.  Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. , 2017, Diabetes research and clinical practice.

[15]  T. Card,et al.  Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study , 2017, BMJ Open.

[16]  M. Stepanova,et al.  Direct and Indirect Economic Burden of Chronic Liver Disease in the United States , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[17]  A. Barritt,et al.  NAFLD and liver transplantation: Current burden and expected challenges. , 2016, Journal of hepatology.

[18]  Robert Blissett,et al.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.

[19]  J. Piercy,et al.  Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme , 2016, BMJ Open.

[20]  K. Payne,et al.  Reporting Guidelines for the Use of Expert Judgement in Model-Based Economic Evaluations , 2016, PharmacoEconomics.

[21]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[22]  R. Baran,et al.  Costs and absence of HCV-infected employees by disease stage , 2015, Journal of medical economics.

[23]  T. Card,et al.  Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography , 2015, BMJ Open.

[24]  G. Cesana,et al.  The societal burden of chronic liver diseases: results from the COME study , 2015, BMJ open gastroenterology.

[25]  L. Mantovani,et al.  Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options , 2015, Journal of viral hepatitis.

[26]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[27]  Eliseo Guallar,et al.  Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. , 2013, American journal of epidemiology.

[28]  Y. Yazdanpanah,et al.  49 LIFETIME COSTS ATTRIBUTABLE TO CHRONIC HEPATITIS C FROM THE FRENCH HEALTHCARE PERSPECTIVE (ANRS N°12188) , 2013 .

[29]  N. Chalasani,et al.  Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .

[30]  Michael Charlton,et al.  The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.

[31]  J. Moss,et al.  Cost-of-Illness Studies , 2011, PharmacoEconomics.

[32]  J. Piercy,et al.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes – a means to understand , 2008, Current medical research and opinion.

[33]  H. Kleven,et al.  The Marginal Cost of Public Funds: Hours of Work Versus Labor Force Participation , 2006 .

[34]  U. Siebert,et al.  Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: A health technology assessment commissioned by the German Federal Ministry of Health and Social Security , 2005, International Journal of Technology Assessment in Health Care.

[35]  Stirling Bryan,et al.  An empirical comparison of EQ-5D and SF-6D in liver transplant patients. , 2003, Health economics.

[36]  Livio Garattini,et al.  Durata e costo delle visite in medicina generale: il progetto DYSCO , 2003 .

[37]  H. Kleven,et al.  The Marginal Cost of Public Funds in OECD Countries; Hours of Work Versus Labor Force Participation , 2003, SSRN Electronic Journal.

[38]  G. Koëter,et al.  The cost effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands , 2003, Transplant international : official journal of the European Society for Organ Transplantation.

[39]  A. Zbrozek,et al.  The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument , 1993, PharmacoEconomics.

[40]  E. Bugianesi,et al.  The Cost of Non-Alcoholic Steatohepatitis (NASH) in Europe and USA: The GAIN Study , 2019, Social Science Research Network.

[41]  John Paul Gosling,et al.  SHELF: The Sheffield Elicitation Framework , 2018 .

[42]  A. Burroughs,et al.  Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. , 2015, Health technology assessment.

[43]  F. Colombo.  Help wanted? : providing and paying for long-term care , 2011 .

[44]  W. B. van den Hout,et al.  The value of productivity: human-capital versus friction-cost method , 2009, Annals of the Rheumatic Diseases.

[45]  J. Piercy,et al.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. , 2008, Current medical research and opinion.

[46]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[47]  S. P. Akpabio.  World Health Organisation , 1983, British Dental Journal.

[48]  José Antonio Flaquer.  Conversaciones con don Ernesto Marco Cañizares, presidente del Consejo General de Colegios Oficiales de Farmacéuticos , 1973 .

[49]  G. Reed.  Social security. , 1959, Hospital progress.